Can Gradual Dose Titration of Ketamine for Management of Neuropathic Pain Prevent Psychotomimetic Effects in Patients With Advanced Cancer?
- 24 July 2012
- journal article
- research article
- Published by SAGE Publications in American Journal of Hospice and Palliative Medicine®
- Vol. 30 (5) , 450-454
Abstract
Ketamine is often used to manage neuropathic pain in patients with cancer. However, it occasionally causes psychotomimetic effects such as vivid dreams, nightmares, illusions, hallucinations, and altered body image. Objective: To examine whether gradual dose titration of ketamine for management of neuropathic pain prevents psychotomimetic effects in patients with advanced cancer. This was a retrospective chart review. We administered ketamine when neuropathic pain in patients with advanced cancer became refractory to opioids and oral adjuvant analgesics. The starting dose of ketamine was 10 mg/d by continuous intravenous infusion. The dose was gradually increased by 10 mg/d every 4 to 6 hours to 50 mg/d or until the pain was relieved. It was subsequently increased by 25 mg/d every 12 to 24 hours until the pain was relieved. For this study, we enrolled 46 patients with advanced cancer. The mean age was 52.2 ± 16.9 years. The mean dose at onset of action and maximum dose of ketamine were 56 ± 58 and 272 ± 214 mg/d, respectively. The mean pain intensity (numerical rating scale) decreased significantly from 7.3 ± 2.0 to 3.5 ± 2.2 after the administration of ketamine (P < .01). The effectiveness was 69.5%. No psychotomimetic effect of less than 300 mg/d was observed during the introduction phase even though psychotropic drugs were not prescribed. Mild sedation was observed in 3 patients (7%) as the only adverse effect during the introduction phase. Gradual dose titration of ketamine for management of neuropathic pain can prevent psychotomimetic effects in patients with advanced cancer.Keywords
This publication has 24 references indexed in Scilit:
- NMDA Receptor Antagonists for the Treatment of Neuropathic PainPain Medicine, 2010
- Ketamine spares morphine consumption after transthoracic lung and heart surgery without adverse hemodynamic effects☆Pharmacological Research, 2008
- Successful use of ketamine for intractable cancer painSupportive Care in Cancer, 2004
- Ketamine as Adjuvant Analgesic to Opioids: A Quantitative and Qualitative Systematic ReviewAnesthesia & Analgesia, 2004
- Subanesthetic ketamine: an essential adjuvant for intractable cancer painJournal of Pain and Symptom Management, 2004
- The Synergistic Effect of Combined Treatment with Systemic Ketamine and Morphine on Experimentally Induced Windup-Like Pain in HumansAnesthesia & Analgesia, 2004
- “Burst” Ketamine for Refractory Cancer PainJournal of Pain and Symptom Management, 2001
- Analgesic Effect of Intravenous Ketamine in Cancer Patients on Morphine TherapyJournal of Pain and Symptom Management, 2000
- Analgesic Effect of Oral Ketamine in Chronic Neuropathic Pain of Spinal OriginJournal of Pain and Symptom Management, 1999
- Effective treatment of severe cancer pain of the head using low-dose ketamine in an opioid-tolerant patientJournal of Pain and Symptom Management, 1995